Roivant Sciences Ltd. (ROIV)
35.72
+0.22
(+0.62%)
USD |
NASDAQ |
Oct 02, 16:00
35.68
-0.04
(-0.11%)
After-Hours: 20:00
Roivant Sciences Max Drawdown (5Y) : 79.22% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 79.22% |
| August 31, 2026 | 79.22% |
| July 31, 2026 | 79.22% |
| June 30, 2026 | 79.22% |
| May 31, 2026 | 79.22% |
| April 30, 2026 | 79.22% |
| Date | Value |
|---|---|
| March 31, 2026 | 79.22% |
| February 28, 2026 | 79.22% |
| January 31, 2026 | 79.22% |
| December 31, 2025 | 79.22% |
| November 30, 2025 | 79.22% |
| October 31, 2025 | 79.22% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Oxford Biomedica Plc | 90.85% |
| Bicycle Therapeutics Plc | 94.11% |
| Arbutus Biopharma Corp. | 84.78% |
| Adaptimmune Therapeutics Plc | 100.00% |
| Kiniksa Pharmaceuticals International Plc | 75.43% |